Mga Batayang Estadistika
| CIK | 1807120 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Design Therapeutics, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 7, 2025 |
Exhibit 99.2 |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40288 Design Therapeutics, Inc. |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 07, 2025 Design Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40288 82-3929248 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 7, 2025 |
Exhibit 99.1 Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results Early Human Pharmacokinetics Data for DT-216P2 Demonstrates Favorable Translation from non-human primates (NHPs) to Humans and Improved DT-216 Product Profile for Friedreich Ataxia (FA) Program RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2 in FA Pati |
|
| June 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2025 Design Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40288 82-3929248 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 14, 2025 |
DESIGN THERAPEUTICS, INC. 6005 Hidden Valley Road, Suite 110 Carlsbad, California 92011 CORRESP DESIGN THERAPEUTICS, INC. 6005 Hidden Valley Road, Suite 110 Carlsbad, California 92011 May 14, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jessica Dickerson Re: Design Therapeutics, Inc. Registration Statement on Form S-3 (File No. 333-287043) Filed: May 7, 2025 Request for Acceleration of Effective |
|
| May 7, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Design Therapeutics, Inc. |
|
| May 7, 2025 |
Form of Common Stock Warrant Agreement and Warrant Certificate. EX-4.8 Exhibit 4.8 DESIGN THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF DESIGN THERAPEUTICS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between DESIGN THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized an |
|
| May 7, 2025 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. EX-4.9 Exhibit 4.9 DESIGN THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF DESIGN THERAPEUTICS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between DESIGN THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] org |
|
| May 7, 2025 |
As filed with the Securities and Exchange Commission on May 7, 2025 Table of Contents As filed with the Securities and Exchange Commission on May 7, 2025 Registration No. |
|
| May 7, 2025 |
Exhibit 99.1 Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results Phase 1 Single Ascending Dose Trial of DT-216P2 for Friedreich Ataxia (FA) Program Ongoing Reported Favorable Phase 1 Data for DT-168 for Fuchs Endothelial Corneal Dystrophy (FECD) Program Well-Capitalized with Cash and Securities of $229.7 Million to Fund Operations |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40288 Design Therapeutics, Inc. |
|
| May 7, 2025 |
Form of Indenture, between the registrant and one or more trustees to be named. Exhibit 4.6 DESIGN THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20[•] Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificat |
|
| May 7, 2025 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. EX-4.10 Exhibit 4.10 DESIGN THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF DESIGN THERAPEUTICS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between DESIGN THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] o |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 07, 2025 Design Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40288 82-3929248 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40288 Design Therapeu |
|
| March 10, 2025 |
Exhibit 99.1 Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results Initiated Phase 1 Single Ascending Dose Trial of DT-216P2 in Healthy Volunteers; Friedreich Ataxia (FA) Patient Dosing to Begin in mid-2025 Dosing Complete in DT-168 Phase 1 Healthy Volunteer Trial, with Data on Track for the First Half of 2025; Enrollm |
|
| March 10, 2025 |
As filed with the Securities and Exchange Commission on March 10, 2025 As filed with the Securities and Exchange Commission on March 10, 2025 Registration No. |
|
| March 10, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Design Therapeutics, Inc. |
|
| March 10, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2025 Design Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40288 82-3929248 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 10, 2025 |
Insider Trading Policy of the Registrant. Exhibit 19.1 DESIGN THERAPEUTICS, INC. INSIDER TRADING POLICY Persons Covered This Insider Trading Policy of Design Therapeutics, Inc. (the “Company”) applies to all directors, officers, other employees and consultants of the Company and any subsidiaries. It also applies to their family members who reside with them, anyone else who lives in their households and any family members who do not live i |
|
| January 13, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 Design Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40288 82-3929248 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| January 13, 2025 |
Exhibit 99.1 |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2024 Design Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40288 82-3929248 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 7, 2024 |
Exhibit 99.1 Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio Fuchs Endothelial Corneal Dystrophy (FECD) Phase 1 Trial Initiated with Data Expected in the First Half of 2025 Friedreich Ataxia (FA) Program on Track to Initiate Phase 1 Single Ascending Dose, Healthy Volunteer Study in the First Half of 2025 Active Research Pi |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40288 Design Therapeutics, Inc. |
|
| August 13, 2024 |
DSGN / Design Therapeutics, Inc. / Logos Global Management LP Activist Investment SC 13D/A 1 dsgn13d.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) Design Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 25056L103 (CUSIP Number) Derek Gould Logos Global Management LP One Letterman Drive, Building C, Suite C3-350 San Fr |
|
| August 5, 2024 |
Exhibit 99.1 Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio Friedreich Ataxia (FA) and Fuchs Endothelial Corneal Dystrophy (FECD) Programs on Track and Advancing Toward Clinical Trials Active Research Pipeline with Programs Progressing in Myotonic Dystrophy Type-1 (DM1) and Huntington’s Disease (HD) Cash and Securities o |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 05, 2024 Design Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40288 82-3929248 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40288 Design Therapeutics, Inc. |
|
| June 17, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2024 Design Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40288 82-3929248 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 8, 2024 |
Exhibit 99.1 Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones Advancing DT-216P2, New Drug Product for Friedreich Ataxia (FA), Toward Clinical Trials Starting Phase 1 Development for Fuchs Endothelial Corneal Dystrophy (FECD) in 2024; Observational Study Currently Enrolling Patients Progressing GeneTACTM Pipeline Programs in Huntington’s |
|
| May 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2024 Design Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40288 82-3929248 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40288 Design Therapeutics, Inc. |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40288 Design Therapeu |
|
| March 19, 2024 |
Exhibit 99.1 Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results New Drug Product for Friedreich Ataxia (FA) DT-216P2 with Favorable Nonclinical Pharmacokinetic and Injection Site Safety Profile; Complete GLP Studies by Year-end 2024 to Start Patient Trials in 2025 IND Cleared for DT-168 for Treatment of Fuchs Endothelial |
|
| March 19, 2024 |
Exhibit 10.13 DESIGN THERAPEUTICS, INC. THIRD AMENDMENT TO CONSULTING AGREEMENT THIS THIRD AMENDMENT TO CONSULTING AGREEMENT (“Amendment”) is made this 9th day of November 2023, by DESIGN THERAPEUTICS, INC. and ASEEM Z. ANSARI, PhD, parties to that certain Consulting Agreement dated December 27, 2017 (“Agreement”). 1. Section 2.2 of Exhibit A to the Agreement is amended and restated in its entiret |
|
| March 19, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2024 Design Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40288 82-3929248 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 19, 2024 |
Non-Employee Director Compensation Policy Exhibit 10.7 DESIGN THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to Design Therapeutics, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy for hi |
|
| March 19, 2024 |
Exhibit 4.3 DESCRIPTION OF COMMON STOCK The following summary description of the common stock of Design Therapeutics, Inc. (we, our or us) is based on the provisions of our amended and restated certificate of incorporation, as well as our amended and restated bylaws, and the applicable provisions of the Delaware General Corporation Law. This information is qualified entirely by reference to the ap |
|
| March 19, 2024 |
Consulting Agreement by and between the Registrant and Rodney Lappe, Ph.D., dated November 22, 2023. Exhibit 10.14 DESIGN THERAPEUTICS, INC. CONSULTING AGREEMENT This Consulting Agreement (the “Agreement”) is entered into as of November 22, 2023, (the “Effective Date”) by and between Design Therapeutics, Inc., a Delaware corporation (the “Client”), and Rodney Lappe, Ph.D. (“Consultant”). Whereas, the Client desires to retain Consultant as an independent contractor to perform consulting services f |
|
| March 19, 2024 |
As filed with the Securities and Exchange Commission on March 19, 2024 As filed with the Securities and Exchange Commission on March 19, 2024 Registration No. |
|
| March 19, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Design Therapeutics, Inc. |
|
| March 19, 2024 |
Design Therapeutics, Inc. Incentive Compensation Recoupment Policy Exhibit 97.1 DESIGN THERAPEUTICS, INC. Incentive Compensation Recoupment Policy 1. Introduction The Board of Directors (the “Board”) of Design Therapeutics, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) providing for the Company’s recoupment of |
|
| February 14, 2024 |
DSGN / Design Therapeutics, Inc. / CITADEL ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A 1 tm243953d3sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 2)* Design Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (the “Shares” |
|
| February 14, 2024 |
SC 13G/A 1 schedule13ga.htm AMENDMENT NO. 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Design Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 25056L103 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate bo |
|
| November 14, 2023 |
DSGN / Design Therapeutics Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm2330558d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* DESIGN THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 25056L 10 3 (CUSIP Number) November 14, 2023 (Date of Event Which Requires Filing of this Statem |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40288 Design Therapeutics, Inc. |
|
| November 13, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 Design Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40288 82-3929248 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 13, 2023 |
Separation Agreement by and between the Company and João Siffert, M.D., dated August 25, 2023. Exhibit 10.1 6005 Hidden Valley Road, Suite 110 Carlsbad, CA 92011 August 25, 2023 João Siffert, M.D. Re: Separation Agreement Dear João: This letter sets forth the substance of the separation agreement (the “Agreement”) that Design Therapeutics, Inc. (the “Company”) is offering to you to aid in your employment transition. 1. Separation. In connection with a mutual separation, you hereby submit, a |
|
| November 13, 2023 |
Exhibit 99.1 Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024 Seasoned Biotech Executive Pratik Shah Appointed as Chief Executive Officer to Lead Company Turnaround Current Cash and Securities of ~$290M Support Extended Five-Year Operating Runway Through 2028 Revised Corporate Strategy with Realignment Towards Long-Term G |
|
| August 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2023 Design Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40288 82-3929248 (State or other jurisdiction of incorporation) (Commissi |
|
| August 14, 2023 |
Phase 1 MAD Study FXN mRNA Skeletal Muscle Response Chart Exhibit 99.1 Phase 1 MAD Study Clinical Activity Significant and prolonged FXN mRNA increase in skeletal muscle Muscle FXN mRNA response correlated with dose and muscle DT-216 exposure, p < 0.05* Cohorts: 200mg and 300mg Muscle FXN mRNA (mean % change from baseline) p < 0.05** NS** 75th% FA † 40 20 0 -20 -40 2 Days 7 Days Days After 3rd Weekly Dose Pooled Placebo (n=6) DT-216 200mg (n=7) DT-216 30 |
|
| August 14, 2023 |
Exhibit 99.1 Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results Initial Data from Phase 1 Multiple-Ascending Dose Trial of DT-216 for Friedreich Ataxia Showed Significant Increase in FXN mRNA Levels in Skeletal Muscle Company Expects to Resume a Multiple Dose Phase 1 Clinical Study with DT-216 with an Improved Formulation in the Second Half of 2024 and R |
|
| August 14, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 Design Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40288 82-3929248 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40288 Design Therapeutics, Inc. |
|
| June 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2023 Design Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40288 82-3929248 (State or other jurisdiction of incorporation) (Commission |
|
| May 9, 2023 |
Exhibit 99.1 Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial Results Initial Data from Phase 1 Multiple-Ascending Dose Trial of DT-216 for Friedreich Ataxia Expected in the Third Quarter of 2023 Progress Across GeneTAC™ Small Molecule Pipeline with IND Submissions for FECD and DM1 Programs On-track for the Second Half of 2023 and 2024, Respectively $315.4 Mil |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2023 Design Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40288 82-3929248 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40288 Design Therapeutics, Inc. |
|
| April 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 3, 2023 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Shares of Design Therapeutics, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the under |
|
| April 3, 2023 |
DSGN / Design Therapeutics Inc / CITADEL ADVISORS LLC - DESIGN THERAPEUTICS, INC. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* Design Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (the “Shares”) (Title of Class of Securities) 25056L103 |
|
| March 14, 2023 |
As filed with the Securities and Exchange Commission on March 14, 2023 As filed with the Securities and Exchange Commission on March 14, 2023 Registration No. |
|
| March 14, 2023 |
Exhibit 99.1 Design Therapeutics Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results Phase 1 Multiple-Ascending Dose Trial of DT-216 for Friedreich Ataxia Ongoing with Data Expected Mid-Year Continued Progress Across Pipeline of GeneTACTM Small Molecules with Three Programs Expected to be in Clinical Development in the Next Two Years Strong Financial Positi |
|
| March 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40288 Design Therapeu |
|
| March 14, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Design Therapeutics, Inc. |
|
| March 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2023 Design Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40288 82-3929248 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| February 14, 2023 |
DSGN / Design Therapeutics Inc / CITADEL ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A 1 tm233474-27sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1)* Design Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (the “Shares |
|
| February 14, 2023 |
DSGN / Design Therapeutics Inc / Cormorant Asset Management, LP Passive Investment SC 13G/A 1 schedule13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Design Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 25056L103 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| December 22, 2022 |
SCHEDULE 13D JOINT FILING AGREEMENT Exhibit 2 SCHEDULE 13D JOINT FILING AGREEMENT In accordance with the requirements of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and subject to the limitations set forth therein, the parties set forth below agree to jointly file the Schedule 13D to which this joint filing agreement is attached, and any subsequent amendments thereto, and have duly executed this joint filing agreement as of the date set forth below. |
|
| December 22, 2022 |
Exhibit 3 LIMITED POWER OF ATTORNEY Know all by these presents, that the undersigned hereby makes, constitutes and appoints Sasha Keough, Karen Narolewski-Engel, James Macadam, and Alexander M. |
|
| December 22, 2022 |
DSGN / Design Therapeutics Inc / SR One Capital Fund I Aggregator LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Design Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 25056L 10 3 (CUSIP Number) Sasha Keough c/o SR One Capital Management, LP 985 Old Eagle School Road, Suite 511 Wayne, PA 19087 410-800-7503 (Name, |
|
| December 22, 2022 |
DSGN / Design Therapeutics Inc / CITADEL ADVISORS LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 (Amendment No. )* Design Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (the ?Shares?) (Title of Class of Securities) 25056L103 |
|
| December 22, 2022 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Shares of Design Therapeutics, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the under |
|
| December 22, 2022 |
Exhibit 1 Trade Date Number of Shares Average Price Per Share* Low Price High Price Where/How Effected 12/16/2022 500,000 $ 8. |
|
| November 3, 2022 |
Exhibit 99.1 Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results Initial Data from Single-Ascending Dose Phase 1 Trial of DT-216 for Friedreich Ataxia Expected to be Reported in December 2022 Dosing Initiated in the Multiple-Ascending Dose Phase 1 Trial of DT-216; Trial Completion Anticipated in Mid-2023 Strong Financial Positio |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40288 Design Therapeutics, Inc. |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 03, 2022 Design Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40288 82-3929248 (State or Other Jurisdiction of Incorporation) (Commis |
|
| October 13, 2022 |
DSGN / Design Therapeutics Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* DESIGN THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 25056L 10 3 (CUSIP Number) October 3, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40288 Design Therapeutics, Inc. |
|
| August 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 08, 2022 Design Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40288 82-3929248 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 8, 2022 |
Exhibit 99.1 Design Therapeutics Highlights Upcoming Milestones and Reports Second Quarter 2022 Financial Results Initial Data from Friedreich Ataxia Phase 1 Trial of DT-216 Expected in the Fourth Quarter of 2022 Strong Financial Position with $359.4 Million in Cash and Securities to Support Multi-Year Operating Runway Carlsbad, Calif., Aug. 8, 2022 ? Design Therapeutics, Inc. (Nasdaq: DSGN), a cl |
|
| June 16, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2022 Design Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40288 82-3929248 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 9, 2022 |
Exhibit 99.1 Design Therapeutics Highlights Clinical and Research Progress and Reports First Quarter 2022 Financial Results Clinical Execution of Lead GeneTACTM Molecule, DT-216, with Initiation of Phase 1 Trial for the Treatment of Friedreich Ataxia Robust Research Pipeline of GeneTACTM Candidates, with Promising New Data for Fuchs Endothelial Corneal Dystrophy Strong Cash Position with $371.2 Mi |
|
| May 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2022 Design Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40288 82-3929248 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40288 Design Therapeutics, Inc. |
|
| May 5, 2022 |
DESIGN THERAPEUTICS, INC. 6005 Hidden Valley Road, Suite 110 Carlsbad, California 92011 DESIGN THERAPEUTICS, INC. 6005 Hidden Valley Road, Suite 110 Carlsbad, California 92011 May 5, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Dorrie Yale Re: Design Registration Statement on Form S-3 (File No. 333-264521) Filed: April 27, 2022 Request for Acceleration of Effective Date Ladies and Gentlemen: Des |
|
| May 2, 2022 |
DESIGN THERAPEUTICS, INC. 6005 Hidden Valley Road, Suite 110 Carlsbad, California 92011 DESIGN THERAPEUTICS, INC. 6005 Hidden Valley Road, Suite 110 Carlsbad, California 92011 May 2, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Dorrie Yale Re: Design Therapeutics, Inc. Registration Statement on Form S-3 (File No. 333-264521) Filed: April 27, 2022 Request for Acceleration of Effective Date Ladies |
|
| April 27, 2022 |
Open Market Sale AgreementSM, dated April 27, 2022, by and between the Registrant and Jefferies LLC. Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM April 27, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Design Therapeutics, Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the ?Agent?), shares of the Company?s common |
|
| April 27, 2022 |
Form of Common Stock Warrant Agreement and Warrant Certificate. Exhibit 4.8 DESIGN THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF DESIGN THERAPEUTICS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between DESIGN THERAPEUTICS, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and exist |
|
| April 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 27, 2022 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. Exhibit 4.9 DESIGN THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF DESIGN THERAPEUTICS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between DESIGN THERAPEUTICS, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized |
|
| April 27, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Design Therapeutics, Inc. |
|
| April 27, 2022 |
As filed with the Securities and Exchange Commission on April 27, 2022 As filed with the Securities and Exchange Commission on April 27, 2022 Registration No. |
|
| April 27, 2022 |
Form of Indenture, between the registrant and one or more trustees to be named. Exhibit 4.6 DESIGN THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 20[?] Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certificate |
|
| April 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 27, 2022 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.10 DESIGN THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF DESIGN THERAPEUTICS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between DESIGN THERAPEUTICS, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized |
|
| March 31, 2022 |
DSGN / Design Therapeutics Inc / Logos Global Management LP Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) Design Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 25056L103 (CUSIP Number) Virginia Yee Logos Global Management LP One Letterman Drive, Building C, Suite C3-350 San Francisco, CA 94129 Telep |
|
| March 22, 2022 |
Exhibit 10.1 FIRST AMENDMENT TO LEASE This First Amendment to Lease (?First Amendment?) is entered into and effective as of March 18, 2022 (?Effective Date?) by and between CROSSING HOLDINGS, LLC, a California limited liability company (?Landlord?) and DESIGN THERAPEUTICS, INC, a Delaware corporation (?Tenant?), with reference to the recitals set forth below: RECITALS A. Landlord and Tenant entere |
|
| March 22, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2022 Design Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40288 82-3929248 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 10, 2022 |
EX-FILING FEES 4 d320439dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Design Therapeutics, Inc. (Exact name of Registrant as Specified in its Charter) Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Fe |
|
| March 10, 2022 |
Description of the Registrant’s Common Stock. Exhibit 4.3 DESCRIPTION OF COMMON STOCK The following summary description of the common stock of Design Therapeutics, Inc. (we, our or us) is based on the provisions of our amended and restated certificate of incorporation, as well as our amended and restated bylaws, and the applicable provisions of the Delaware General Corporation Law. This information is qualified entirely by reference to the ap |
|
| March 10, 2022 |
Exhibit 10.3 Design Therapeutics, Inc. 2021 Equity Incentive Plan Adopted by the Board of Directors: March 18, 2021 Approved by the Stockholders: March 19, 2021 Table of Contents Page 1. General. 1 2. Shares Subject to the Plan. 1 3. Eligibility and Limitations. 2 4. Options and Stock Appreciation Rights. 3 5. Awards Other Than Options and Stock Appreciation Rights. 7 6. Adjustments upon Changes i |
|
| March 10, 2022 |
Exhibit 99.1 Design Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results Phase 1 Trial of DT-216, a Novel FA GeneTACTM Molecule, in Patients with Friedreich Ataxia On Track to Begin Soon Preclinical Data Supporting Development of Novel GeneTACTM Small Molecules for the Treatment of Fuchs Endothelial Corneal Dystrophy (FECD) to be Presented at |
|
| March 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40288 Design Therapeu |
|
| March 10, 2022 |
As filed with the Securities and Exchange Commission on March 10, 2022 As filed with the Securities and Exchange Commission on March 10, 2022 Registration No. |
|
| March 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2022 Design Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40288 82-3929248 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| February 14, 2022 |
DSGN / Design Therapeutics Inc / Cormorant Asset Management, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Design Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 25056L103 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| February 9, 2022 |
DSGN / Design Therapeutics Inc / Ansari Aseem Z. - SC 13G Passive Investment SC 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 Design Therapeutics, Inc. |
|
| February 9, 2022 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 Design Therapeutics, Inc. |
|
| February 9, 2022 |
CUSIP No. 25056L 103 13G EXHIBIT A Joint Filing Agreement In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the persons named below agrees to the joint filing of a Statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Design Therapeutics, Inc. a Delaware corporation. Dated: February 8, 2022 Star Irrevocable Trust |
|
| February 9, 2022 |
13G CUSIP No. 25056L 103 EXHIBIT A Joint Filing Agreement In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the persons named below agrees to the joint filing of a Statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Design Therapeutics Inc., a Delaware corporation. Dated: February 8, 2022 Light Irrevocable Trust |
|
| February 9, 2022 |
SC 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 Design Therapeutics, Inc. |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40288 Design Therapeutics, Inc. |
|
| November 9, 2021 |
Exhibit 99.1 Design Therapeutics Reports Pipeline Progress and Third Quarter 2021 Results Clinical Initiation of Lead GeneTACTM Program for Friedreich Ataxia On-track for the First Half of 2022 Carlsbad, CA, Nov. 9, 2021 ? Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today reported recent pipeline progress and third qua |
|
| November 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2021 Design Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40288 82-3929248 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2021 Design Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40288 82-3929248 (State or other jurisdiction of incorporation) (Commissi |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40288 Design Therapeutics, Inc. |
|
| August 9, 2021 |
Exhibit 99.1 Design Therapeutics Reports GeneTAC? Portfolio Progress and Second Quarter 2021 Results Preclinical Data Support Initiation of Clinical Development of Lead GeneTAC Program for Friedreich Ataxia in the First Half of 2022 Leadership Team Strengthened with Appointment of Elizabeth Gordon, Ph.D., as Senior Vice President of Regulatory Affairs Carlsbad, CA, Aug. 9, 2021 ? Design Therapeuti |
|
| August 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2021 Design Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-40288 (Commission File Numb |
|
| August 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2021 Design Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40288 82-3929248 (State or other jurisdiction of incorporation) (Commissio |
|
| June 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8?K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2021 Design Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-40288 (Commission File Number |
|
| May 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8?K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2021 Design Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-40288 (Commission File Number |
|
| May 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40288 Design Therapeutics, Inc. |
|
| May 10, 2021 |
Exhibit 99.1 Design Therapeutics Announces Business Highlights and Reports First Quarter 2021 Financial Results Successful $276 Million IPO Completed to Advance GeneTACTM Programs for Friedreich Ataxia and Myotonic Dystrophy Type-1 Toward Clinical Development Company On-track to Initiate Phase 1 Clinical Trial for the Treatment of Friedreich Ataxia in the First Half of 2022 Carlsbad, CA, May 10, 2 |
|
| April 9, 2021 |
SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Design Therapeutics, Inc. (Name of Issuer) Common Stock, Par Value $0.0001 (Title of Class of Securities) 25056L 10 3 (CUSIP Number) Karen Narolewski Engel c/o SR One Capital Management, LP 985 Old Eagle School Road, Suite 511 Wayne, PA 19087 610-7 |
|
| April 9, 2021 |
Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of April 9, 2021, is by and among Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare Fund II, LP, Cormorant Private Healthcare GP II, LLC, Cormorant Private Healthcare Fund III, LP, Cormorant Private Healthcare GP III, LLC, Cormorant Asset Management, LP and Bihua C |
|
| April 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Design Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 25056L103 (CUSIP Number) March 30, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| March 30, 2021 |
8-K 1 d108026d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2021 Design Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40288 82-3929248 (State or other jurisdiction of |
|
| March 30, 2021 |
Exhibit 99.1 Design Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters? Option to Purchase Additional Shares Carlsbad, CA, March 30, 2021 ? Design Therapeutics, Inc. (Nasdaq: DSGN) (?Design?), a biotechnology company developing a platform of gene targeted chimera (GeneTAC?) small molecules for the treatment of serious degenerative disorders caused by inheri |
|
| March 30, 2021 |
Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF DESIGN THERAPEUTICS, INC. ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 2. Other Offices. The corporation shall also have and maintain an office or principal place of business at such place as may be fixed by the corporatio |
|
| March 30, 2021 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF DESIGN THERAPEUTICS, INC. Jo?o Siffert, M.D., hereby certifies that: ONE: He is the duly elected Chief Executive Officer of Design Therapeutics, Inc., a Delaware corporation. TWO: The date of filing the original Certificate of Incorporation of the Company with the Secretary of State of the State of Delaware was December 18, 2017. THR |
|
| March 26, 2021 |
As filed with the Securities and Exchange Commission on March 26, 2021 Registration No. |
|
| March 26, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-253954 12,000,000 Shares Common Stock This is the initial public offering of shares of common stock of Design Therapeutics, Inc. We are offering 12,000,000 shares of our common stock. Prior to this offering, there has been no public market for our common stock. The initial public offering price is $20.00 per share of our commo |
|
| March 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Design Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 82-3929248 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification N |
|
| March 23, 2021 |
DESIGN THERAPEUTICS, INC. 6005 Hidden Valley Road, Suite 110 Carlsbad, CA 92011 DESIGN THERAPEUTICS, INC. 6005 Hidden Valley Road, Suite 110 Carlsbad, CA 92011 March 23, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jeanne Bennett Vanessa Robertson Kasey Robinson Jeffrey Gabor Re: Design Therapeutics, Inc. Registration Statement on Form S-1, as amended (File No. 333-253954) Request for Ac |
|
| March 23, 2021 |
March 23, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jeanne Bennett Vanessa Robertson Kasey Robinson Jeffrey Gabor Re: Design Therapeutics, Inc. Registration Statement on Form S-1, as amended (File No. 333-253954) Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 under th |
|
| March 22, 2021 |
Exhibit 10.8 DESIGN THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the ?Board?) who is not also serving as an employee of or consultant to Design Therapeutics, Inc. (the ?Company?) or any of its subsidiaries (each such member, an ?Eligible Director?) will receive the compensation described in this Non-Employee Director Compensation Policy for hi |
|
| March 22, 2021 |
Exhibit 10.12 DESIGN THERAPEUTICS, INC. CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (?Agreement?) is entered into as of December 27, 2017, by and between DESIGN THERAPEUTICS, INC., a Delaware corporation having its principal place of business located at 991C Lomas Santa Fe #436, Solana Beach, CA 92075 (collectively with its affiliates, ?Company?), and ASEEM Z. ANSARI, PhD (?Consultant?). The Co |
|
| March 22, 2021 |
Exhibit 4.1 DESIGN THERAPEUTICS NUMBER DT SHARES INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE CUSIP 25056L 10 3 SEE REVERSE FOR CERTAIN DEFINITIONS AND LEGENDS This certifies that is the record holder of FULLY PAID AND NONASSESSABLE SHARES OF COMMON STOCK, $0.0001 PAR VALUE PER SHARE, OF Design Therapeutics, Inc. transferable on the books of the Corporation in person or by duly authorized |
|
| March 22, 2021 |
DESIGN THERAPEUTICS CONSULTING AGREEMENT EFFECTIVE DATE: March 1, 2020 Exhibit 10.10 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. DESIGN THERAPEUTICS CONSULTING AGREEMENT EFFECTIVE DATE: March 1, 2020 THIS CONSULTING AGREEMENT (the ?Agreement?) is made as of the Effective Date set forth above by and between Design Therap |
|
| March 22, 2021 |
Exhibit 10.4 DESIGN THERAPEUTICS, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MARCH 18, 2021 APPROVED BY THE STOCKHOLDERS: MARCH 19, 2021 1. GENERAL; PURPOSE. (a) The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company t |
|
| March 22, 2021 |
Amended and Restated Certificate of Incorporation, as currently in effect. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF DESIGN THERAPEUTICS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Design Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), DOES HEREBY CERTIFY: 1. Tha |
|
| March 22, 2021 |
Kenneth J. Rollins +1 858 550 6136 [email protected] March 22, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jeanne Bennett, Vanessa Robertson, Kasey Robinson and Jeffrey Gabor Re: Design Therapeutics, Inc. Registration Statement on Form S-1 Filed March 5, 2021 File No. 333-253954 Ladies and Gentlemen: On behalf of De |
|
| March 22, 2021 |
Table of Contents As filed with the Securities and Exchange Commission on March 22, 2021. |
|
| March 22, 2021 |
Exhibit 10.3 DESIGN THERAPEUTICS, INC. 2021 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MARCH 18, 2021 APPROVED BY THE STOCKHOLDERS: March 19, 2021 TABLE OF CONTENTS Page 1. GENERAL. 1 2. SHARES SUBJECT TO THE PLAN. 1 3. ELIGIBILITY AND LIMITATIONS. 2 4. OPTIONS AND STOCK APPRECIATION RIGHTS. 3 5. AWARDS OTHER THAN OPTIONS AND STOCK APPRECIATION RIGHTS. 7 6. ADJUSTMENTS UPON CHANGES I |
|
| March 16, 2021 |
*FOIA Confidential Treatment Request* Confidential Treatment Requested by Design Therapeutics, Inc. |
|
| March 5, 2021 |
Kenneth J. Rollins +1 858 550 6136 [email protected] March 5, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jeanne Bennett, Vanessa Robertson, Kasey Robinson and Jeffrey Gabor Re: Design Therapeutics, Inc. Draft Registration Statement on Form S-1 Submitted January 26, 2021 CIK No. 0001807120 Ladies and Gentlemen: On b |
|
| March 5, 2021 |
Exhibit 10.5 DESIGN THERAPEUTICS, INC. March 1, 2020 Pratik Shah, Ph.D. Re: Offer of Employment Dear Pratik: Design Therapeutics, Inc. (the ?Company?) is pleased to offer you at-will employment in the position of Executive Chairperson on the terms and conditions set forth in this letter agreement (the ?Agreement?). 1. Employment by the Company. Your employment with the Company shall begin on the l |
|
| March 5, 2021 |
Exhibit 10.7 DESIGN THERAPEUTICS, INC. May 21, 2019 Sean Jeffries Re: Employment Terms Dear Sean: Design Therapeutics, Inc. (the ?Company?) is pleased to offer you the position of Principal scientist/Chief Business Officer on the terms set forth below. This offer is subject to the following conditions: ? As required by law, the Company receipt of satisfactory proof of your right to work in the Uni |
|
| March 5, 2021 |
Table of Contents As filed with the Securities and Exchange Commission on March 5, 2021. |
|
| March 5, 2021 |
Form of Underwriting Agreement. Exhibit 1.1 Design Therapeutics, Inc. Common Stock Underwriting Agreement [?], 2021 Goldman Sachs & Co. LLC SVB Leerink LLC Piper Sandler & Co. As representatives (the ?Representatives?) of the several Underwriters named in Schedule I hereto, c/o Goldman Sachs & Co. LLC 200 West Street, New York, New York 10282-2198 c/o SVB Leerink LLC One Federal Street, 37th Floor Boston, Massachusetts 02110 c/o |
|
| March 5, 2021 |
Exhibit 10.9 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Agreement No. [***] HUMAN THERAPEUTICS EXCLUSIVE LICENSE AGREEMENT This Human Therapeutics Exclusive License Agreement (?Agreement?) is made effective the 20th day of February, 2019 (?Effective |
|
| March 5, 2021 |
Exhibit 10.10 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. DESIGN THERAPEUTICS CONSULTING AGREEMENT EFFECTIVE DATE: March 1, 2020 THIS CONSULTING AGREEMENT (the ?Agreement?) is made as of the Effective Date set forth above by and between Design Therap |
|
| March 5, 2021 |
Exhibit 10.6 DESIGN THERAPEUTICS, INC. September 21, 2020 Joao Siffert Re: Offer of Employment Dear Joao: Design Therapeutics, Inc. (the ?Company?) is pleased to offer you at-will employment in the position of Chief Executive Officer (?CEO?) on the terms and conditions set forth in this letter agreement (the ?Agreement?). 1. Employment by the Company. Your employment with the Company shall begin o |
|
| March 5, 2021 |
Exhibit 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF DESIGN THERAPEUTICS, INC. Jo?o Siffert, M.D., hereby certifies that: ONE: He is the duly elected Chief Executive Officer of Design Therapeutics, Inc., a Delaware corporation. TWO: The date of filing the original Certificate of Incorporation of the Company with the Secretary of State of the State of Delaware was December 18, 2017. THR |
|
| March 5, 2021 |
Bylaws, as currently in effect. Exhibit 3.3 BYLAWS OF DESIGN THERAPEUTICS, INC. (A DELAWARE CORPORATION) ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be 251 Little Falls Drive, City of Wilmington, County of New Castle, 19808 or in such other location as the Board of Directors of the corporation (the ?Board of Directors?) may from time to time determine or |
|
| March 5, 2021 |
Exhibit 4.2 AMENDED AND RESTATED INVESTORS? RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTORS? RIGHTS AGREEMENT (this ?Agreement?), is made as of January 25, 2021, by and among Design Therapeutics, Inc., a Delaware corporation (the ?Company?), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an ?Investor?. RECITALS: A. The Company and certain |
|
| March 5, 2021 |
Exhibit 10.11 LEASE This Lease (?Lease?) is made and dated as of February 2, 2021 (?Effective Date?), by and between CROSSING HOLDINGS, LLC, a California limited liability company (?Landlord?) and DESIGN THERAPEUTICS, INC., a Delaware corporation (?Tenant?). NOW, THEREFORE, in consideration of the foregoing, and the mutual covenants and agreements contained in this Lease, and intending to be legal |
|
| March 5, 2021 |
Exhibit 10.1 INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this ?Agreement?) dated as of , 20 , is made by and between DESIGN THERAPEUTICS, INC., a Delaware corporation (the ?Company?), and (?Indemnitee?). RECITALS A. The Company desires to attract and retain the services of highly qualified individuals as directors, officers, employees and agents. B. The Company?s Amended and Restated Bylaws (the |
|
| March 5, 2021 |
Exhibit 10.2 DESIGN THERAPEUTICS, INC. 2018 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: June 18, 2018 APPROVED BY THE STOCKHOLDERS: June 18, 2018 AMENDEDMENT ADOPTED BY THE BOARD OF DIRECTORS: October 29, 2020 AMENDMENT APPROVED BY THE STOCKHOLDERS: November 17, 2020 TERMINATION DATE: June 17, 2028 1. GENERAL. (a) Eligible Stock Award Recipients. Employees, Directors and Consultants a |
|
| March 5, 2021 |
Amended and Restated Certificate of Incorporation, as currently in effect. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF DESIGN THERAPEUTICS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Design Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), DOES HEREBY CERTIFY: 1. Tha |
|
| March 5, 2021 |
Form of Amended and Restated Bylaws to become effective upon the closing of this offering. Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF DESIGN THERAPEUTICS, INC. ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 2. Other Offices. The corporation shall also have and maintain an office or principal place of business at such place as may be fixed by the corporatio |
|
| January 26, 2021 |
Exhibit 10.7 DESIGN THERAPEUTICS, INC. May 21, 2019 Sean Jeffries Re: Employment Terms Dear Sean: Design Therapeutics, Inc. (the ?Company?) is pleased to offer you the position of Principal scientist/Chief Business Officer on the terms set forth below. This offer is subject to the following conditions: ? As required by law, the Company receipt of satisfactory proof of your right to work in the Uni |
|
| January 26, 2021 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF DESIGN THERAPEUTICS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Design Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), DOES HEREBY CERTIFY: 1. Tha |
|
| January 26, 2021 |
DESIGN THERAPEUTICS CONSULTING AGREEMENT EFFECTIVE DATE: March 1, 2020 Exhibit 10.11 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. DESIGN THERAPEUTICS CONSULTING AGREEMENT EFFECTIVE DATE: March 1, 2020 THIS CONSULTING AGREEMENT (the ?Agreement?) is made as of the Effective Date set forth above by and between Design Therap |
|
| January 26, 2021 |
Exhibit 10.5 DESIGN THERAPEUTICS, INC. March 1, 2020 Pratik Shah, Ph.D. Re: Offer of Employment Dear Pratik: Design Therapeutics, Inc. (the ?Company?) is pleased to offer you at-will employment in the position of Executive Chairperson on the terms and conditions set forth in this letter agreement (the ?Agreement?). 1. Employment by the Company. Your employment with the Company shall begin on the l |
|
| January 26, 2021 |
Table of Contents As confidentially submitted to the Securities and Exchange Commission on January 26, 2021. |
|
| January 26, 2021 |
HUMAN THERAPEUTICS EXCLUSIVE LICENSE AGREEMENT Exhibit 10.10 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Agreement No. [***] HUMAN THERAPEUTICS EXCLUSIVE LICENSE AGREEMENT This Human Therapeutics Exclusive License Agreement (?Agreement?) is made effective the 20th day of February, 2019 (?Effectiv |
|
| January 26, 2021 |
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT Exhibit 4.2 AMENDED AND RESTATED INVESTORS? RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTORS? RIGHTS AGREEMENT (this ?Agreement?), is made as of January 25, 2021, by and among Design Therapeutics, Inc., a Delaware corporation (the ?Company?), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an ?Investor?. RECITALS: A. The Company and certain |
|
| January 26, 2021 |
Exhibit 10.6 DESIGN THERAPEUTICS, INC. September 21, 2020 Joao Siffert Re: Offer of Employment Dear Joao: Design Therapeutics, Inc. (the ?Company?) is pleased to offer you at-will employment in the position of Chief Executive Officer (?CEO?) on the terms and conditions set forth in this letter agreement (the ?Agreement?). 1. Employment by the Company. Your employment with the Company shall begin o |
|
| January 26, 2021 |
BYLAWS DESIGN THERAPEUTICS, INC. (A DELAWARE CORPORATION) Exhibit 3.3 BYLAWS OF DESIGN THERAPEUTICS, INC. (A DELAWARE CORPORATION) ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be 251 Little Falls Drive, City of Wilmington, County of New Castle, 19808 or in such other location as the Board of Directors of the corporation (the ?Board of Directors?) may from time to time determine or |
|
| January 26, 2021 |
Exhibit 10.2 DESIGN THERAPEUTICS, INC. 2018 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: June 18, 2018 APPROVED BY THE STOCKHOLDERS: June 18, 2018 AMENDEDMENT ADOPTED BY THE BOARD OF DIRECTORS: October 29, 2020 AMENDMENT APPROVED BY THE STOCKHOLDERS: November 17, 2020 TERMINATION DATE: June 17, 2028 1. GENERAL. (a) Eligible Stock Award Recipients. Employees, Directors and Consultants a |
